ULTOMIRIS 300 mg/3 ml, concentrate for solution for infusion bottle, 3 ml
Active ingredients: Ravulizumab
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Concentrate for solution for infusionbottle, 3 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ULTOMIRIS 300 mg/3 mL, solution à diluer pour perfusion
- Pharmaceutical form
- solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre de 3 ml
- Marketing authorisation holder
- ALEXION EUROPE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 11 Mar 2022
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61808523CIP75508238CIP133400955082385Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RAVULIZUMABsolution | 300 mg · un flacon de 3 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.